Adverse Events in Pregnant Patients Treated with Coronavirus Disease 2019 Therapeutics
Authors:
- Mark SimonMSMark Simon
- Jennie BuchananJBJennie Buchanan
- Jonathan SchimmelJSJonathan Schimmel
- Jeffrey BrentJBJeffrey Brent
- Keith BurkhartKBKeith Burkhart
- Natalie TaylorNTNatalie Taylor
- Kim AldyKAKim Aldy
- On behalf of the Toxicology Investigators Consortium FACT Study GroupOGOn behalf of the Toxicology Investigators Consortium FACT Study Group
- 15 August 2023
- journal article
- research article
- Published by Springer Nature in Journal of Medical Toxicology
- Vol. 19 (4) , 381-388
Abstract
Background Pregnant patients are at high risk of maternal and fetal complications from Coronavirus Disease 2019 (COVID-19) infections. The COVID-19 pandemic prompted a surge in the development and repurposing of therapies for the SARS-CoV-2 virus. Evidence is sparse on the efficacy and safety of these therapies in pregnant patients. Our objective was to describe adverse events (AEs) to COVID-19 therapeutics in pregnant patients. Methods This was a case series of AEs reported to the FDA ACMT COVID-19 ToxIC (FACT) Pharmacovigilance Project between November 23, 2020, and June 28, 2022. FACT is an ongoing toxicosurveillance project at 17 sites to proactively identify and report AEs associated with COVID-19 therapeutics. Abstracted information includes demographics, case narratives, exposure details, clinical information, pregnancy details, treatments, and outcomes. Results Forty-six COVID-19-positive pregnant patients who developed AEs following COVID-19 therapeutics were reported to the FACT Pharmacovigilance Project over 19 months. The most reported medications were remdesivir in 22 patients (47.8%) and casirivimab/imdevimab in 8 patients (17.4%). Four patients (8.7%) had life-threatening clinical manifestation, and 16 patients (34.8%) required intervention to prevent permanent damage. The most common maternal and fetal events were elevated serum alanine aminotransferase (26.1%) and non-reassuring fetal heart patterns (20.0%), respectively. Conclusions This case series reports AEs of elevated serum alanine aminotransferase, maternal bradycardia, maternal hypothermia, non-reassuring fetal heart patterns, and emergent or unplanned cesarean sections following administration of several COVID-19 therapeutics. This study was not designed to definitely identify causation, and further study is needed to evaluate the causal role of these therapeutics in AEs affecting pregnant COVID-19 patients.Keywords
Funding Information
- U.S. Food and Drug Administration (Contract 75F40119D10031/7540120F19003)
This publication has 27 references indexed in Scilit:
- Myocardial injury associated with coronavirus disease 2019 in pregnancyAmerican Journal of Obstetrics and Gynecology, 2021
- Corticosteroids in the Management of Pregnant Patients With Coronavirus Disease (COVID-19)Obstetrics & Gynecology, 2020
- SARS-CoV-2 infection in pregnancy: A systematic review and meta-analysis of clinical features and pregnancy outcomeseClinicalMedicine, 2020
- Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies: a United States cohort studyAmerican Journal of Obstetrics & Gynecology MFM, 2020
- COVID-19 and liver injury: a meta-analysisEuropean Journal of Gastroenterology & Hepatology, 2020
- Compassionate Use of Remdesivir for Patients with Severe Covid-19New England Journal of Medicine, 2020
- Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19ACS Central Science, 2020
- Protease inhibitors and preterm deliveryAIDS, 2018
- Non-reassuring fetal status: Case definition & guidelines for data collection, analysis, and presentation of immunization safety dataVaccine, 2016
- Premature Delivery in HIV-Infected Women Starting Protease Inhibitor Therapy During Pregnancy: Role of the Ritonavir Boost?Clinical Infectious Diseases, 2012